Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
16 October 2020 | Story Leonie Bolleurs | Photo Supplied
Qinisani Qwabe, one of the Mail & Guardian Top 200 Young South Africans, considers it important to always reach out and contribute to someone's life, no matter how small it may be.

Looking back at 2020, most people will not have fond memories. But for Qinisani Qwabe, a second-year PhD student in the Centre for Sustainable Agriculture, Rural Development and Extension, 2020 turned out to be a good year.

On 10 September, he heard that he was selected as one of the Mail & Guardian Top 200 Young South Africans in the education category. As if being elected as one of the prestigious group of young people is not enough, Qwabe added another feather in his cap when he was chosen as one of 21 young scientists by the Academy of Science of South Africa (ASSAf), in collaboration with the Department of Science and Innovation (DSI). 

When offered the chance to represent South Africa at a BRICS Conference in Russia, he seized the opportunity with both hands. At this virtual event, he presented a paper on a topic he cares about a lot – ecology. His paper, using a South African case study, was titled: The role of agrobiodiversity on environmental management and its impact on human ecology.

Sustainable resources

From an early age, growing up in a very isolated community called iSihuzu on the outskirts of Richards Bay, Qwabe worked hard. He not only reaped the rewards by seeing all his tuition fees paid, but he was also offered opportunities to make a difference in society. 

“I want to see a society that leads a sustainable life and values its natural resources. This is what wakes me up every morning. That is what I am working towards,” he says.

Qwabe has a registered organisation that, among others, seeks to achieve agricultural biodiversity, respect and value for local knowledge, sustainable development, as well as youth and community engagement.  

The organisation has two legs – one dealing with agricultural production and the other focusing on social entrepreneurship. “As part of this social entrepreneurship initiative, we are working with schools in the north of KwaZulu-Natal, where we do outreach programmes (e.g. donating school uniforms), and run projects driven towards sustainability,” says Qwabe.

But he believes that it is his voice on indigenous foods, together with his passion for research – complemented by community development initiatives – that contributed to his selection as one of Mail & Guardian’s top 200 Young South Africans. 

A greater vision

He is happy to be in the academia and believes that it will propel him towards his greater vision. 

“My vision for my future is to be well-known for my contributions on matters of environmental sustainability, and equally so, for community development. Parallel to my philanthropic undertakings, I envision being a leader in one of the leading organisations on environmental sustainability, such as the World Health Organisation's Food and Agricultural Organisation (FAO),” says Qwabe. 

Here he would like to focus his energies on food security, nutrition, and food safety; sustainable management and use of natural resources and forestry; and institutional capacity building for the sustained management of natural resources and increased agriculture production.

The next generation

Qwabe believes he is making an impact and building a solid foundation for the upcoming generations to build upon.  He urges the youth of South Africa to strive to make a difference. “No matter how small it might seem,” he says.

“To borrow from the American songwriter, Michael Jackson – WE are the world. And that 'WEness' denotes that each one of us has a role to play.

 

 

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept